PHASE-II TRIAL OF TITANOCENE DICHLORIDE IN ADVANCED RENAL-CELL CARCINOMA

Authors
LUMMEN G SPERLING H LUBOLDT H OTTO T RUBBEN H
Citation
G. Lummen et al., PHASE-II TRIAL OF TITANOCENE DICHLORIDE IN ADVANCED RENAL-CELL CARCINOMA, Cancer chemotherapy and pharmacology, 42(5), 1998, pp. 415-417
Citations number
10
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Cancer chemotherapy and pharmacology → ACNP
ISSN journal
03445704
Volume
42
Issue
5
Year of publication
1998
Pages
415 - 417
Database
ISI
SICI code
0344-5704(1998)42:5<415:PTOTDI>2.0.ZU;2-2
Abstract
Titanocene dichloride was capable of inhibiting the growth of differen t types of human tumors in vitro. A total of 14 patients with metastat ic renal-cell carcinoma (RCC) received 270 mg/m(2) titanocene dichlori de every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response wa s detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.